Evolv Technologies heads into tomorrow's Q1 earnings report with a story split squarely between accelerating revenue momentum and a steady drip of insider disposals from the company's own founders.
The most telling signal into this print is the insider activity. Founder and Chief Level Officer Michael Ellenbogen sold shares three times since late February — totalling roughly 255,000 shares at prices between $5.10 and $6.32 — while co-founder Anil Chitkara also trimmed holdings across multiple transactions. The CFO followed in early May, selling just over 51,000 shares at $7.27. Net of awards, the 90-day insider figure still reflects cumulative selling of around $2.5 million in aggregate value. That's not a fire-sale volume for a small-cap, but the consistency of the pattern — founders booking gains across multiple weeks as the stock climbed — is worth noting heading into a result.
Short interest is not the headline here. It has dropped nearly 45% over the past month to just 3.9% of the free float, a level that falls well below the threshold for meaningful squeeze pressure. Availability in the lending pool is extremely loose, with very little of available supply currently drawn. Cost to borrow is barely above zero at 0.48%. None of that says the bears are crowding in ahead of earnings. Options positioning reinforces the same read — the put/call ratio of 0.24 is modestly above its 20-day average but sits near the bottom of the 52-week range, indicating that call interest continues to dominate. Investors in the options market are leaning bullish, not defensive.
The bull case rests on a growth story with real numbers behind it. Analysts estimated revenue near $43.7 million for the quarter, which would represent continued expansion from the 29% year-on-year growth Evolv posted in its most recent full-year results. The subscription model pivot — moving toward direct fulfillment — is a structural shift that bulls argue improves recurring revenue quality and cash conversion. The mean analyst price target of $10.00 sits roughly 44% above the current price of $6.96, and the analyst direction of travel has been consistently upward since mid-2025, with Lake Street upgrading to Buy and Cantor Fitzgerald lifting its target. That said, all of the cited analyst actions are more than six months old, so the consensus reflects a view formed earlier in the recovery rather than current positioning.
Bears point to Evolv's persistent losses — the company is still burning cash, with operating cash flow expected to remain negative — and the revenue recognition questions that have historically dogged the story. A slowdown in new system orders or weakness in net retention would threaten the subscription economics thesis. The EV/EBITDA multiple, while compressing, remains elevated at 70x on trailing figures, leaving little margin for execution shortfall. The prior earnings print, from March, saw the stock jump 10.6% the following day and hold a 2.1% gain five days out — a modest positive template, though a single data point.
The print is therefore a test of whether Evolv's subscription transition is delivering the revenue quality and cash flow improvement the bulls have been pricing in — and whether founder selling reflects routine planning or a more cautious read on near-term upside.
See the live data behind this article on ORTEX.
Open EVLV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
